Skip to main content

Advertisement

Table 2 Effectiveness of treatment across the two treatment groups as assessed by DAS28 and HAQ status and changes at 3 and 6 months

From: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

  RTX 500 mg × 2 RTX 1000 mg × 2 Unadjusted p values (ANOVA) Adjusted p values**
DAS28 baseline 5.7 ± 1.3 (215) 6.1 ± 1.3 (2069) <0.0001  
DAS28 3 m 4.4 ± 1.2 (138) 4.2 ± 1.3 (1046) 0.15  
DAS28 6 m 4.3 ± 1.3 (109) 4.3 ± 1.2 (1385) 0.99  
DeltaDAS28 3 m –1.3 ± 1.3 (125) –1.9 ± 1.4 (991) <0.0001 0.004
DeltaDAS28 6 m –1.7 ± 1.4 (100) –2.0 ± 1.3 (1344) 0.02 0.23
HAQ baseline 1.6 ± 0.7 (212) 1.6 ± 0.7 (1584) 0.48  
HAQ 3 m 1.3 ± 0.7 (127) 1.3 ± 0.7 (957) 0.83  
HAQ 6 m 1.2 ± 0.7 (109) 1.3 ± 0.7 (912) 0.21  
DeltaHAQ 3 m –0.3 ± 0.5 (115) –0.5 ± 0.6 (859) 0.02 0.10
DeltaHAQ 6 m -0.4 ± 0.6 (103) –0.5 ± 0.7 (826) 0.13 0.27
  1. Crude and adjusted p valued are presented. **Analysis of covariance (ANCOVA) adjusted for age, sex, disease duration, number of prior biologic agents used, baseline Disease Activity Score in 28 joints (DAS28), concomitant use of disease-modifying anti-rheumatic drugs and glucocorticoids. RTX rituximab, HAQ Health Assessment Questionnaire, m months